AI Terminal
Hutchmed (China) Limited
Transaction in Own Shares • Dec 31, 2020
10503_rns_2020-12-31_4ca32b03-320b-49c5-b12f-1b5d8b41fda9.html
Transaction in Own Shares
Open in ViewerOpens in native device viewer
National Storage Mechanism | Additional information 
RNS Number : 1384K
Hutchison China Meditech Limited
31 December 2020
Blocklisting Six Monthly Return
London: Thursday, December 31, 2020: Hutchison China MediTech Limited ("Chi-Med" or the "Company") (AIM/Nasdaq: HCM) announces the following blocklisting six monthly return:
| 1. | Name of applicant: | Hutchison China MediTech Limited | ||
| 2. | Name of scheme: | (a) | Share Option Scheme conditionally adopted by Hutchison China MediTech Limited in 2005 ("2005 HCML Share Option Scheme") | |
| (b) | Share Option Scheme conditionally adopted by Hutchison China MediTech Limited in 2015 ("2015 HCML Share Option Scheme") | |||
| (c) | Warrant instrument granted by Hutchison China MediTech Limited on June 25, 2020 ("Warrant") | |||
| 3. | Period of return: | From June 29, 2020 to December 28, 2020 | ||
| 4. | Balance under scheme from previous return: | (a) | 2005 HCML Share Option Scheme: 1,738,910 ordinary shares of US$0.1 each | |
| (b) | 2015 HCML Share Option Scheme: 23,130,970 ordinary shares of US$0.1 each | |||
| 5. | The amount by which the block scheme has been increased, if the scheme has been increased since the date of the last return: | (a) | 2005 HCML Share Option Scheme: Nil | |
| (b) | 2015 HCML Share Option Scheme: 30,221,458 ordinary shares of US$0.1 each | |||
| (c) | Warrant: 16,666,670 ordinary shares of US$0.1 each | |||
| 6. | Number of securities issued/allotted under scheme during period: | (a) | 2005 HCML Share Option Scheme: 400,000 ordinary shares of US$0.1 each | |
| (b) | 2015 HCML Share Option Scheme: 80,780 ordinary shares of US$0.1 each | |||
| (c) | Warrant: nil | |||
| 7. | Balance under scheme not yet issued/allotted at end of the period: | (a) | 2005 HCML Share Option Scheme: 1,338,910 ordinary shares of US$0.1 each | |
| (b) | 2015 HCML Share Option Scheme: 53,271,648 ordinary shares of US$0.1 each | |||
| (c) | Warrant: 16,666,670 ordinary shares of US$0.1 each | |||
| 8. | Number and class of securities originally listed and the date of admission: | (a) | 25,198,880 ordinary shares of US$0.1 each admitted on June 17, 2019 (to replace the Company's previous block admission schemes following the Company's share subdivision which took effect on May 30, 2019) | |
| (b) | 16,666,670 ordinary shares of US$0.1 each admitted on July 6, 2020 |
| 9. | Total number of securities in issue at the end of the period: | 727,722,215 ordinary shares of US$0.1 each | |
| Name of contact: | Christian Hogg | ||
| Address of contact: | Level 18, The Metropolis Tower, 10 Metropolis Drive, Hung Hom, Kowloon, Hong Kong | ||
| Telephone number of contact: | +852 2121 8200 |
About Chi-Med
Chi-Med (Nasdaq/AIM: HCM) is an innovative biopharmaceutical company committed, over the past twenty years, to the discovery and global development of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. It has a portfolio of nine cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. For more information, please visit: www.chi-med.com.
CONTACTS
| Investor Enquiries | |
| Mark Lee, Senior Vice President | +852 2121 8200 |
| Annie Cheng, Vice President | +1 (973) 567 3786 |
| Media Enquiries | |
| Americas - Brad Miles, Solebury Trout | +1 (917) 570 7340 (Mobile) [email protected] |
| Europe - Ben Atwell / Alex Shaw, FTI Consulting | +44 20 3727 1030 / +44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile) [email protected] |
| Asia - Joseph Chi Lo / Zhou Yi, Brunswick | +852 9850 5033 (Mobile), [email protected] / +852 9783 6894 (Mobile), y[email protected] |
| Nominated Advisor | |
| Freddy Crossley / Atholl Tweedie, Panmure Gordon (UK) Limited | +44 (20) 7886 2500 |
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
BLRURRRRRBUUOAA